Qualitative Study About Psychedelics Using in Psychiatric Disorders

University Hospital, Toulouse25 enrolled

Overview

This study is set up to better understand the current use of psychedelics in France in the general population. The present focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. The data are collected during a semi-structured interview and then studied in a thematic analysis.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Psychiatric Disorder

Interventions

InterviewDIAGNOSTIC_TEST

An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with a psychiatric disorder by a psychiatrist or general practitioner * Patients used psychedelic or related substances in order to treat psychiatric symptoms * Patients have given their oral non-opposition * Patients affiliated to a social security scheme Exclusion Criteria: * Patients who don't speak or understand French * Patients under protection, guardianship or curators

Outcomes

Primary Outcomes

Experiences of people using psychedelic substances

Experiences description of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview

Time frame: Baseline

Secondary Outcomes

Profile of people using psychedelic substances

The profile of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview

Time frame: Baseline

Central Contacts

Antoine YRONDI, MD

CONTACT

0561778603 yrondi.a@chu-toulouse.fr

Paul ROCHEFORT

CONTACT

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.